CIK 0001671858 · Non-accelerated filer<br>Smaller reporting company
ARS Pharmaceuticals, Inc.
Sign in to watch- Ticker
- SPRY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811489190
- Phone
- 858-771-9307
- Business address
- 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Silverback Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-04 | Chakma Justin Chief Business Officer | Sale | −45,000 | $13.95 | $628K | 136,380 |
| 2024-12-04 | Chakma Justin Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −45,000 | 149,640 | ||
| 2024-12-04 | Shawver Laura Director | Option exercise 10b5-1 | +14,772 | $3.15 | $47K | 225,118 |
| 2024-12-04 | Shawver Laura Director | Sale 10b5-1 | −14,772 | $13.75 | $203K | 210,346 |
| 2024-12-04 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,772 | 59,064 | ||
| 2024-12-04 | Karas Eric Chief Commercial Officer | Option exercise 10b5-1 | +6,283 | $1.50 | $9K | 11,976 |
| 2024-12-04 | Karas Eric Chief Commercial Officer | Sale 10b5-1 | −6,283 | $14.00 | $88K | 5,693 |
| 2024-12-04 | Karas Eric Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,283 | 584,588 | ||
| 2024-12-03 | Chakma Justin Chief Business Officer | Option exercise | +3,260 | $0.84 | $3K | 139,640 |
| 2024-12-03 | Chakma Justin Chief Business Officer | Option exercise | +41,740 | $0.84 | $35K | 181,380 |
| 2024-12-03 | Chakma Justin Chief Business Officer | Sale | −45,000 | $13.19 | $593K | 136,380 |
| 2024-12-03 | Chakma Justin Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −3,260 | 0 | ||
| 2024-12-03 | Chakma Justin Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −41,740 | 194,640 | ||
| 2024-12-03 | Shawver Laura Director | Option exercise 10b5-1 | +25,606 | $1.27 | $33K | 235,952 |
| 2024-12-03 | Shawver Laura Director | Option exercise 10b5-1 | +62,378 | $3.15 | $196K | 298,330 |
| 2024-12-03 | Shawver Laura Director | Sale 10b5-1 | −87,984 | $13.26 | $1.2M | 210,346 |
| 2024-12-03 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,606 | 0 | ||
| 2024-12-03 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −62,378 | 73,836 | ||
| 2024-12-02 | Chakma Justin Chief Business Officer | Option exercise | +45,000 | $0.84 | $38K | 181,380 |
| 2024-12-02 | Chakma Justin Chief Business Officer | Sale | −45,000 | $13.67 | $615K | 136,380 |
Page 8 of 14 · 267 trades